Financials Codexis, Inc.

Equities

CDXS

US1920051067

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-05-31 pm EDT 5-day change 1st Jan Change
3.38 USD -0.59% Intraday chart for Codexis, Inc. +6.62% +10.82%

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 935.7 1,388 2,029 306.1 213 238.5 - -
Enterprise Value (EV) 1 935.7 1,388 2,029 306.1 213 238.5 238.5 238.5
P/E ratio -76.1 x -54.6 x -94.8 x -9.14 x -2.72 x -5.07 x -5 x -12.1 x
Yield - - - - - - - -
Capitalization / Revenue 13.7 x 20.1 x 19.4 x 2.21 x 3.04 x 3.67 x 3.72 x 2.74 x
EV / Revenue 13.7 x 20.1 x 19.4 x 2.21 x 3.04 x 3.67 x 3.72 x 2.74 x
EV / EBITDA -232 x -97.4 x -254 x -10.4 x -3.4 x -6.11 x -5.22 x -
EV / FCF -57.4 x -60.8 x -56.8 x -133 x -3.73 x -3.98 x -5.78 x -13.9 x
FCF Yield -1.74% -1.64% -1.76% -0.75% -26.8% -25.1% -17.3% -7.2%
Price to Book - - - - - - - -
Nbr of stocks (in thousands) 58,518 63,568 64,875 65,687 69,830 70,558 - -
Reference price 2 15.99 21.83 31.27 4.660 3.050 3.380 3.380 3.380
Announcement Date 2/27/20 2/25/21 2/24/22 2/23/23 2/28/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 68.46 69.06 104.8 138.6 70.14 64.96 64.05 87.03
EBITDA 1 -4.036 -14.24 -7.991 -29.48 -62.55 -39.05 -45.71 -
EBIT 1 -12.55 -23.92 -22.7 -34.88 -68.07 -46.62 -45.45 -16.29
Operating Margin -18.33% -34.64% -21.67% -25.17% -97.04% -71.76% -70.95% -18.71%
Earnings before Tax (EBT) 1 -11.92 -23.67 -21.09 -33.32 -76.17 -47.98 -47.2 -22.2
Net income 1 -11.94 -24.01 -21.28 -33.59 -76.24 -47.05 -47.88 -22.2
Net margin -17.43% -34.77% -20.31% -24.24% -108.69% -72.43% -74.75% -25.51%
EPS 2 -0.2100 -0.4000 -0.3300 -0.5100 -1.120 -0.6662 -0.6757 -0.2800
Free Cash Flow 1 -16.29 -22.82 -35.69 -2.294 -57.06 -59.86 -41.27 -17.16
FCF margin -23.8% -33.04% -34.07% -1.66% -81.34% -92.15% -64.43% -19.72%
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share - - - - - - - -
Announcement Date 2/27/20 2/25/21 2/24/22 2/23/23 2/28/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 24.5 35.34 38.41 34.47 30.38 12.98 21.32 9.277 26.56 17.07 8.275 15.49 24.86 13 13.78
EBITDA 1 -6.369 -3.333 1.963 -4.7 -8.879 -19.39 -8.358 -27.29 1.498 - -16.04 -11.54 -1.198 -16.8 -16.61
EBIT 1 -10.38 -8.386 -2.609 -10.64 -13.25 -23.66 -12.55 -32.06 0.282 -11.89 -17.78 -12.64 -4.014 -12.01 -11.65
Operating Margin -42.39% -23.73% -6.79% -30.86% -43.62% -182.29% -58.88% -345.59% 1.06% -69.63% -214.82% -81.56% -16.15% -92.34% -84.56%
Earnings before Tax (EBT) 1 -10.12 -8.347 -2.532 -9.984 -12.45 -22.6 -11.51 -34.9 -7.157 -11.5 -18 -13.11 -5.062 -12.12 -11.95
Net income 1 -10.19 -8.356 -2.64 -9.992 -12.6 -22.62 -11.52 -34.91 -7.192 -11.5 -18.02 -12.86 -4.237 -12.14 -11.97
Net margin -41.59% -23.64% -6.87% -28.99% -41.5% -174.22% -54.04% -376.29% -27.08% -67.39% -217.78% -82.99% -17.05% -93.33% -86.87%
EPS 2 -0.1600 -0.1300 -0.0400 -0.1500 -0.1900 -0.3400 -0.1700 -0.5000 -0.1000 -0.1600 -0.2600 -0.1843 -0.0514 -0.1720 -0.1720
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 2/24/22 5/5/22 8/4/22 11/3/22 2/23/23 5/4/23 8/3/23 11/2/23 2/28/24 5/2/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt - - - - - - - -
Net Cash position - - - - - - - -
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 -16.3 -22.8 -35.7 -2.29 -57.1 -59.9 -41.3 -17.2
ROE (net income / shareholders' equity) - - - - - - - -
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share - - - - - - - -
Cash Flow per Share 2 - -0.2800 -0.1000 0.1700 -0.7700 -0.5100 - -
Capex 1 3.73 3.75 13.8 8.31 4.42 10 2.75 8.28
Capex / Sales 5.45% 5.43% 13.17% 5.99% 6.3% 15.39% 4.29% 9.52%
Announcement Date 2/27/20 2/25/21 2/24/22 2/23/23 2/28/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
3.38 USD
Average target price
7.125 USD
Spread / Average Target
+110.80%
Consensus
  1. Stock Market
  2. Equities
  3. CDXS Stock
  4. Financials Codexis, Inc.